Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2026 07:45 ET | Source: NanoXplore Inc.

NanoXplore publie son premier Rapport de durabilité

MONTRÉAL, 24 mars 2026 (GLOBE NEWSWIRE) -- NanoXplore Inc. (« NanoXplore » ou la « Société ») (TSX : GRA et OTCQX : NNXPF), chef de file mondial dans le domaine du graphène, est heureuse...
March 24, 2026 07:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

~ Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75%...
March 24, 2026 06:45 ET | Source: UTStarcom Holdings Corp.

UTStarcom Reports Unaudited Financial Results for Second Half and Full Year 2025

HANGZHOU, China, March 24, 2026 (GLOBE NEWSWIRE) -- UTStarcom (the Company) (NASDAQ: UTSI), a global telecommunications infrastructure provider, today reported its unaudited financial results for...
March 24, 2026 02:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...
March 23, 2026 18:25 ET | Source: Galapagos NV

Galapagos en Gilead in vergevorderde gesprekken over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen

Galapagos is van plan een strategische samenwerking aan te gaan met Gilead, na de overname van Ouro Medicines door Gilead De nieuwe partnerstructuur zou aanzienlijk verbeterde financiële voorwaarden...
March 23, 2026 18:25 ET | Source: Galapagos NV

Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms...
March 23, 2026 11:44 ET | Source: Research and Markets

Ferrosilicon Market Poised to Reach $15.4 Billion by 2034 - Asia-Pacific Leads Ferrosilicon Market with Dominant Share and Rising Demand

Dublin, March 23, 2026 (GLOBE NEWSWIRE) -- The "Ferrosilicon Market Report by Type, Application, End User, and Region 2026-2034" has been added to ResearchAndMarkets.com's offering. The global...
March 23, 2026 09:23 ET | Source: Trinity Biotech plc

Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech’s New York Reference Laboratory DUBLIN and NEW YORK,...
March 23, 2026 07:30 ET | Source: Arbutus Biopharma Corporation

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery...
March 23, 2026 07:17 ET | Source: VALNEVA

Pfizer et Valneva annoncent que le candidat vaccin contre la maladie de Lyme démontre une forte efficacité dans l’essai de Phase 3 VALOR

Le candidat vaccin PF-07307405 (LB6V) a démontré une efficacité de plus de 70 % dans la prévention de la maladie de Lyme chez les personnes âgées de cinq ans et plus.Le candidat vaccin a été bien...